GLAS (25) MDWD (60) ACB (58) USNA (61) ⌘ Pro Terminal →

Niagen Bioscience Inc. (NAGE) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell NAGE stock right now?

Niagen Bioscience Inc. (NAGE) currently earns a Roarable Rating of C (Hold — HOLD) with 63/100 RQD Confidence. Solid 64% profit margin (17% return on capital), mixed timing at 11x P/E—hold if owned, no rush to chase.

Q: What is NAGE's 12-month price target and RQD AI Jury consensus?

NAGE's 12-month base price target is $2.56 (range $2 to $8.35), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$2.50 -1.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.49

Niagen Bioscience Inc. (NAGE) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $197.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NAGE Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NAGE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, Niagen Bioscience Inc. (NASDAQ: NAGE) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $2.50 (-1.57% 1D, market cap $197.8M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, NAGE ranks #160 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NAGE compare to GLAS and MDWD in the Health Care sector?

▼

Within the Health Care sector (Medicinal Chemicals and Botanical Products), NAGE carries a Roarable C (63/100 RQD), trailing P/E of 11.4x, gross margin of 64.3%, and ROIC of 16.8%. By comparison, GLAS (Glass House Brands Inc. Subordinate Voting Shares) holds a E grade (25/100 RQD, P/E N/A, ROIC -9.2%, cap $200.6M) and MDWD (MediWound Ltd.) posts a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $178.9M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NAGE?

▼

Per NAGE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001386570), Niagen Bioscience Inc. generated $129.4M in revenue (+29.9% YoY), $17.4M in net income, and $13.5M in free cash flow against $106.4M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.49 (-0.47%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 10.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+2.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NAGE)Realized 20D OHLCV Swing Band: ±7.5%

Deterministic 5-Pillar Attribution (63/100 Composite)

🔍 WHY NAGE SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (29% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (22% of score)

Altman Z-Score 4.40 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$2.69-7.4% Next Q

Q2 (-2Q)

Grade B-$2.49-2.4% Next Q

Q3 (-1Q)

Grade B-$2.43+2.9% Next Q

Current

Grade C$2.50+0.9% Hist 90D α

Trajectory: B (71) → C (63)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NAGE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, NAGE faces multiple-compression risk if 11.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 61.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($2.86) or 200D SMA ($3.92) invalidates the momentum regime and cuts Target Base ($2.56) toward Bear Floor ($2.00).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NAGE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NAGE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 63%NO 37%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

30.230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

4.40>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE3% OF RANGE

L: $2$2.50H: $8

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (64% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C-RQD 24 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on NAGE

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (65)

16.8% ROIC with 64.3% gross margin and 6.83% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 4.40 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (60)

24/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like NAGE

✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (NAGE Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NAGE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.15%⚡ TESTING RESISTANCE

2026-10-30O $2.49H $2.50L $2.32C $2.50VOL 523.9K

RES: $2.70SUP: $2.14SMA50: $2.86SMA200: $3.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NAGE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NAGE Butterfly Map → + Track NAGE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

1.5%/yr Implied 5Y Growth

vs. +29.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NAGE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NAGE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NAGE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NAGE)

Health Care Rank #160 of 1016 ⚔️ GLAS vs NAGE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NAGE vs. GLAS, MDWD, ACB, USNA)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Niagen Bioscience Inc. (NAGE) ranks #160 by composite RQD confidence (63/100, grade C) and #580 by equity capitalization ($197.8M). Within this direct 5-issuer industry benchmark cohort, NAGE leads on earnings valuation at 11.4x trailing P/E, while NAGE leads on capital efficiency and profitability with 16.8% ROIC and 64.3% gross margin. NAGE currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NAGE ACTIVE Niagen Bioscience Inc.	C	63/100	11.4x	64.3%	16.8%	-1.57%	$197.8M	Benchmark Subject
GLAS Glass House Brands Inc. Subordinate Voting Shares	E	25/100	—	42.3%	-9.2%	+1.33%	$200.6M	/glas-vs-nage →
MDWD MediWound Ltd.	C-	60/100	—	—	—	+2.21%	$178.9M	/mdwd-vs-nage →
ACB Aurora Cannabis Inc.	D+	58/100	—	—	—	0.00%	$252.8M	/acb-vs-nage →
USNA USANA Health Sciences Inc.	C-	61/100	24.6x	78.3%	7.9%	-1.91%	$265.0M	/usna-vs-nage →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001386570

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Niagen Bioscience Inc. (NAGE) reported GAAP revenue of $129.4M (+29.9% vs. FY2024 revenue of $99.6M , and +54.9% cumulative change since FY2023) , GAAP net income of $17.4M, operating cash flow of $13.5M, and free cash flow of $13.5M (+11.5% YoY). On the balance sheet, NAGE closed FY2025 with $106.4M in total assets against $0 in total debt (Altman Z-Score: 4.40, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$129.4M	$17.4M	$13.5M	$13.5M	$106.4M	—
FY2024 (FY)	2024-12-31	$99.6M	$8.6M	$12.1M	$12.1M	$68.3M	—
FY2023 (FY)	2023-12-31	$83.6M	-$4.9M	$7.1M	$7.1M	—	—

3. NAGE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NAGE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NAGE compare to GLAS and MDWD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NAGE?

Where is NAGE trading relative to its 50-day, 200-day, and 52-week technical levels?

NAGE last traded at $2.50 (-1.57% on volume of 348,392 shares), positioning the stock -12.59% below its 50-day simple moving average ($2.86) and -36.22% below its 200-day simple moving average ($3.92). Across its 52-week range of $2.32 to $7.95, NAGE sits at the 3.2% percentile with a 14-day RSI of 30.2 (OVERSOLD (<32)) and an implied next-earnings move of ±7.5% ($2.31 to $2.69).

NAGE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell NAGE stock right now?

Niagen Bioscience Inc. (NAGE) currently earns a Roarable Rating of C (Hold — HOLD) with 63/100 RQD Confidence. Solid 64% profit margin (17% return on capital), mixed timing at 11x P/E—hold if owned, no rush to chase.

What is NAGE's 12-month price target and RQD AI Jury consensus?

NAGE's 12-month base price target is $2.56 (range $2 to $8.35), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: NAGE RQD Cockpit NAGE 12M Forecast NAGE Earnings & Move NAGE Dividends & DRIP NAGE Insiders & 13F NAGE Whale Options NAGE Profit Sankey NAGE News & Why